Molecular targets in cancer therapy

Seminars in Oncology Nursing

Volumn 19, Issue 3, 2003, Pages 193-205

  Gale, Danielle M ^a,b  

^a GENENTECH INC   (United States)

^b Genentech BioOncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLORO 4 FLUOROANILINO) 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; CANERTINIB; CELECOXIB; CGP 69846A; CI 1040; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR; GROWTH PROMOTOR; PROTEIN TYROSINE KINASE;

ACNE; ANEMIA; ARTHRALGIA; ASTHENIA; CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL FUNCTION; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CYTOPENIA; DIARRHEA; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; HEADACHE; HUMAN; MEDICAL LITERATURE; MUCOSA INFLAMMATION; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; NURSING; PATIENT CARE; PATIENT EDUCATION; RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; VOMITING; CLINICAL PROTOCOL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; NEOPLASM; NURSING ASSESSMENT; ONCOLOGY NURSING;

ANTINEOPLASTIC PROTOCOLS; ENZYME INHIBITORS; GROWTH SUBSTANCES; HUMANS; NEOPLASMS; NURSING ASSESSMENT; ONCOLOGIC NURSING; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0142121351     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-2081(03)00047-0     Document Type: Article

References (59)

1. Ulrich A. Molecular targets in cancer therapy and their impact on cancer management. Oncology. 63:(suppl 1):2002;1-5
2. Rowinsky E.K., Windle J.J., Von Hoff D.D. Ras protein farnesyltransferase A strategic target for anticancer therapeutic development. J Clin Oncol. 17:1999;3631-3653
3. King M.W., Marchesini S. Signal transduction 2000. 2001;. Available at: http://www.med.unibs.it/~marchesi/signal.html. (accessed April 26, 2001)
4. Rowinsky E.K. Targeting signal transduction The erbB receptor family as a target for therapeutic development. Horiz Cancer Ther. 2:2001;3-13
5. Ulrich A. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212
6. Sedlacek H.H. Kinase inhibitors in cancer therapy A look ahead. Drugs. 59:2000;435-476
7. Khazaie K., Schirrmacher V., Lichtner R.B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev. 12:1993;255-274
8. Wiley H.S., Burke P.M. Regulation of receptor tyrokinase signaling by endocytic trafficking. Traffic. 2:2001;12-18
9. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 19:2000;6102-6114
10. Jost M., Class R., Kari C., et al. A central role of Bcl-X(L) in the regulation of keratinocyte survival by autocrine EGFR ligands. J Invest Dermatol. 112:1999;443-449
11. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364
12. Wikstrand C.J., Bigner D.D. Prognostic applications of the epidermal growth factor receptor and its ligand transforming growth factor-alpha. J Natl Cancer Inst. 90:1998;799-800
13. Baselga J., Hammond L.A. HER-targeted tyrosine-kinase inhibitors. Oncology. 63:(suppl 1):2002;6-16
14. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279
15. Karp D.D., Silberman R., Csudae R. Phase I dose escalation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor CP-358, 774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 18:1999;388a. (abstr 1499)
16. Perez-Soler R., Chachoua A., Huberman M., et al. Determinants of tumor response and survival in patients with relapsing NSCLC treated with Tarceva (erlotinib HCl; OSI-774). Final report of a phase II study. Proceedings of the American Society of Cancer Research Molecular Therapy Symposium. San Diego, CA, November 2002. 2002;. Available at: http://aacr-nci-01.agora.com/abstractviewer
17. Hidalgo M. Phase I/II studies/combination therapy with Tarceva (erlotinib HCl; OSI-774) in head and neck cancer. Presented at The First Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head and Neck Cancer, February 2003, San Jose, CA. 2003
18. Finkler N., Gordon A., Crozier M., et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol. 20:2001;208a. (abstr 831)
19. Pollack V.A., Savage D.M., Baker D.A., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774 Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 291:1999;739-748
20. Baselga J., Herbst R., LoRusso P., et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types evidence of activity and good tolerability. Proc Am Soc Clin Oncol. 19:2000;177. (abstr 684)
21. Ferry D., Hammond L., Ranson M., et al. Intermittent oral ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity final results of a phase I study. Proc Am Soc Clin Oncol. 19:2000;3. (abstr 5E)
22. Goss G., Hirte H., Batist G., et al. A phase I/II pharmacokinetic and pharmacodynamic study of ZD1839 (Iressa). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients with colorectal cancer. Eur J Cancer. 37:2001;s289. (abstr)
23. Fukouka M., Yano S., Giaccone G., et al. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL1). Proc Am Soc Clin Oncol. 21:2002;298a. (abstr)
24. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who failed platinum and docetaxel-based regimens (IDEAL2). Proc Am Soc Clin Oncol. 21:2002;292a. (abstr 1166)
25. Goss G., Stewart D., Hirte H., et al. Initial results of part 2 of a phase I/II pharmacokinetic, pharmacodynamic and biological activity study of ZD1839 (Iressa) NCIC CTG IND 122. Proc Am Soc Clin Oncol. 21:2002;161. (abstr 59)
26. Cohen E.E., Rosen F., Dekker A., et al. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol. 21:2002;225a. (abstr 899)
27. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD1839 in combination with cisplatin and gemcitabine in chemotherapy- naïve patients with advanced non-small cell lung cancer. Abstracts of the 27th Congress of Europ Soc for Med Oncology. Ann Oncol. 13:(suppl 5):2002;2. (abstr 4)
28. Johnson D.H., Herbst R., Giaccone G., et al. ZD 1839 in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer Results from a phase III clinical trial (INTACT-2). Abstracts of the 27th Congress of Europ Soc for Med Oncology. Ann Oncol. 13:(suppl 5):2002;127. (abstr 468)
29. Zinner RG, Nemunaitis JJ, Donato NJ, et al. A phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033. Proceedings of the American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC). Available at: http://aacr-nci-01.agora.com/abstractviewer, (abstr 566)
30. Reinhart J.J., Wilding G., Willson J, et al. A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with solid tumors. Proc Am Soc Clin Oncol. 21:2002;11a. (abstr 41)
31. Garrison M.A., Tolcher A., McCreery H., et al. A phase I and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor given orally on days 1, 8, and 15 every 28 days to patients with solid tumours. Proc Am Soc Clin Oncol. 20:2001;72a. (abstr 283)
32. Hidalgo M., Erlichman C., Rowinsky E., et al. Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 21:2002;17a. (abstr 65)
33. DiSimone P.A., Bence A.K., Anderson E.B., et al. A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. Proc Am Soc Clin Oncol. 21:2002;94a. (abstr 375)
34. Murren J.R., Papadimitrakopoulou V.A., Sizer K.C., et al. A phase I dose escalating study to evaluate the biological activity and pharmacokinetics of PKI-116, a novel tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 21:2002;951. (abstr 377)
35. Hoekstra R, Dumez H, Eskens FALM, et al. A phase I and pharmacological study of intermittent dosing of PKI-116, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally to patients with advanced cancer. Proceedings of the American Association for Cancer Research (AACR)-National Cancer Institue (NCI)-European Organization for Research and Treatment of Cancer (EORTC). Available at: http://aacr-nci-01.agora.com/ abstractviewer, (abstr 585)
36. Dumez H., Hoekstra R., Eskens F., et al. A phase I and pharmacological study of PKI-116, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced solid tumors. Proc Am Soc Clin Oncol. 21:2002;86a. (abstr 341)
37. Griffen J. The biology of signal transduction inhibition basic science to novel therapies. Semin Oncol. 28:(suppl 17):2001;3-8
38. Kantarjian H.M., Talpaz M. Imatinib mesylate Clinical results in Philadelphia chromosome-positive leukemia. Semin Oncol. 28:(suppl 17):2001;9-18
39. Hochhaus A., Fischer T., Bruemmendorf T., et al. Combination therapy of chronic myelogenous leukemia (CML) with imatinib and pegylated interfeuron α 2a. Proc Am Soc Clin Oncol. 22:2003;569. (abstr)
40. Demetri G. Targeting c-kit mutations in solid tumors scientific rationale and novel therapeutic options. Semin Oncol. 28:(suppl 17):2001;19-26
41. George D. Platelet-derived growth factor receptors a therapeutic target in solid tumors. Semin Oncol. 28:(suppl 17):2001;27-33
42. Kuhn J.G., Prados M., Robins H.I. Phase I trial of R115777 (Zarnestra) in patients with recurrent malignant glioma taking enzyme inducing antiepileptic drugs (EIAED). A North American brain tumor consortium (NABTC) report. Proc Am Soc Clin Oncol. 21:2003;86a. (abstr 342)
43. Cloughesy T.F., Kuhn J., Wen P., et al. Phase II trial of R 115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED) A North American brain tumor consortium (NABTC) report. Proc Am Soc Clin Oncol. 21:2002;80a. (abstr 317)
44. Adejei A.A., Mauer A., Marks R., et al. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 21:2002;290a. (abstr 1156)
45. Heymach J.V., De Porre P.M., DeVore R.F., et al. Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer. Proc Am Soc Clin Oncol. 21:2002;319a. (abstr 1275)
46. Cunningham D., De Gramont A., Scheithauer W., et al. Randomized double-blind placebo-controlled trial of farnesyl transferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol. 21:2002;126a. (abstr 502)
47. Van Custem A., Karasek P., Oettle H., et al. Phase II trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc Am Soc Clin Oncol. 21:2002;130a. (abstr 517)
48. Macdonald J.S., Chansky K., Whitehead R., et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol. 21:2002;138a. (abstr 548)
49. Adjei A. Protein farnesyl transferase as a target for the development of anticancer drugs. Drugs Fut. 25:2000;1069-1079
50. LoRusso P.M., Adjei A.A., Meyer M.B., et al. A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol. 21:2002;81a. (abstr 321)
51. Mitchell D.Y., Reid J.M., Parchment R.E., et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral MEK inhibitor CI-1040, following multiple dose administration to patients with advanced cancer. Proc Am Soc Clin Oncol. 21:2002;81a. (abstr 320)
52. Dang C.T., Shapiro C.L., Hudis C.A. Potential role of selective COX-2 inhibitors in cancer management. Oncology. 16:(suppl):2002;30-36
53. Stratton M.S., Alberts D.S. Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology. 16:(suppl):2002;37-49
54. Tang X., Sun Y.J., Half E., et al. Cyclooxygenase-2 overexpression confers resistance to cell death induced by 5-fluorouracil and TRAIL. Proc Am Soc Clin Oncol. 21:2002;286b. (abstr 2963)
55. Davies G.L.S., Salter J., Hills M., et al. Cyclooxygenase-2 (COX-2) expression in human breast cancer - Correlations with known biological variables and rationale for the use of COX-2 inhibitors. Proc Am Soc Clin Oncol. 21:2002;44a. (abstr 174)
56. Frogge M.H. Teaching Peers and Patients About Monoclonal Antibodies. Oncology Education Services monograph. 2002;Oncology Nursing Society, Pittsburgh, PA
57. Ewell P.T. Organizing for learning. A new imperative. AAHE Bulletin. 50:1997;3-6
58. Sorrentino C., Berger A.M., Wardian S., et al. Using the intranet to deliver patient-education materials. Clin J Oncol Nurs. 6:2002;354-357
59. nd ed:2001;647-669 Jones & Bartlett, Sudbury, MA